NewsBenzinga报告称，BridgeBio 的 Encaleret 提高了骨转换，3 期 CALIBRATE 研究中 100% 的参与者至少一项 ADH1 症状得到改善，而标准治疗组为 46% 报告称，BridgeBio 的 Encaleret 提高了骨转换，3 期 CALIBRATE 研究中 100% 的参与者至少一项 ADH1 症状得到改善，而标准治疗组为 46% Benzinga 2026.10.12 07:04 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Overweight on Essential Properties, Lowers Price Target to $30 Morgan Stanley Maintains Equal-Weight on Sportradar Gr, Lowers Price Target to $13.5 Morgan Stanley Maintains Underweight on Simmons First Ntl, Raises Price Target to $27 Wells Fargo Maintains Equal-Weight on EPR Properties, Lowers Price Target to $56 Analyst Sees Billions in Walmart's Next Big Advertising Opportunity Morgan Stanley Maintains Equal-Weight on Red Rock Resorts, Lowers Price Target to $59
